PCN93 Cost-Effectiveness Analysis of DEB-TACE Compared to Lipiodol-TACE As First LINE Treatment for Unresectable HCC
Dec 1, 2020, 00:00 AM
10.1016/j.jval.2020.08.230
https://www.valueinhealthjournal.com/article/S1098-3015(20)32486-4/fulltext
Section Title :
Section Order :
10179
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32486-4&doi=10.1016/j.jval.2020.08.230